Maternal Pharmacogenomic Profiles During Pregnancy: Clinical Implications and Advances

Abstract

Pharmacogenomics, the study of how genetic differences affect individual drug responses, is gaining traction in maternal-fetal medicine. During pregnancy, dynamic physiological and metabolic changes alter drug pharmacokinetics and pharmacodynamics, complicating optimal pharmacotherapy. Understanding maternal pharmacogenomic profiles can guide safer, more effective medication choices, minimize adverse drug reactions, and improve maternal and fetal outcomes. This review synthesizes current evidence on the clinical utility of pharmacogenomic profiling in pregnancy, explores mechanisms underlying gene-drug interactions, and highlights recent advances and guideline-based recommendations for integrating pharmacogenomics into obstetric care.

Introduction

The application of pharmacogenomics in pregnancy represents a frontier in personalized medicine, aiming to individualize pharmacologic therapy for expectant mothers. Pregnancy induces complex biological changes, including modifications in hepatic enzyme activity, plasma volume, and renal clearance, which can significantly impact drug metabolism and efficacy. Additionally, genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors further modulate therapeutic and adverse drug responses. With the increasing prevalence of medication use during pregnancy—ranging from antiemetics and antibiotics to chronic disease therapies—clinicians face critical challenges in balancing maternal benefits and fetal safety. This review addresses the current landscape of maternal pharmacogenomic profiling, focusing on clinical relevance, recent research, and future directions.

Epidemiology / Disease Burden

Medication use in pregnancy is common, with studies indicating that more than 90% of pregnant women take at least one prescription or over-the-counter drug. Polypharmacy is particularly prevalent among women with chronic health conditions such as epilepsy, hypertension, diabetes, and psychiatric disorders. Adverse drug reactions (ADRs) remain a significant concern, contributing to maternal morbidity, hospitalizations, and, in rare instances, fetal harm. The burden of suboptimal drug therapy is underscored by interindividual variability in drug metabolism, much of which is genetically determined. Epidemiological data highlight the need for personalized pharmacotherapy to mitigate risks and optimize therapeutic outcomes during pregnancy.

Pathophysiology

The pharmacogenomics of pregnancy is shaped by interplay between maternal genetic variants and pregnancy-induced physiological changes. Key genes encode cytochrome P450 enzymes (e.g., CYP2D6, CYP3A4, CYP2C9), UDP-glucuronosyltransferases (UGTs), and drug transporters (e.g., ABCB1), all of which may exhibit altered expression or activity during gestation. For example, CYP2D6 activity typically increases, influencing the metabolism of antidepressants and beta-blockers, while CYP1A2 activity decreases, affecting caffeine and certain antipsychotics. Placental expression of drug-metabolizing enzymes and transporters further modulates fetal drug exposure. Genetic polymorphisms can result in poor, intermediate, extensive, or ultra-rapid drug metabolism phenotypes, directly impacting maternal drug levels and fetal safety.

Risk Factors

Risk factors for clinically significant gene-drug interactions during pregnancy include the presence of high-risk genetic polymorphisms (e.g., CYP2C19*2/*3, CYP2D6*4), use of medications with narrow therapeutic indices (e.g., anticonvulsants, anticoagulants), underlying comorbidities necessitating pharmacotherapy, and concomitant use of multiple drugs subject to metabolic interactions. Ethnic variability in allele frequencies further influences risk profiles; for instance, certain CYP2D6 variants are more prevalent in Asian or African populations. Environmental factors, such as smoking or dietary habits, may modulate gene expression and compound risk.

Clinical Features

Although pharmacogenomic profiles themselves are asymptomatic, their clinical impact manifests as variable drug efficacy, unexpected toxicity, or adverse drug reactions. In pregnancy, this may lead to subtherapeutic responses (e.g., inadequate seizure control in CYP2C9 poor metabolizers taking phenytoin), heightened toxicity (e.g., codeine-induced respiratory depression in CYP2D6 ultra-rapid metabolizers), or altered fetal outcomes. Recognition of these patterns is critical for timely intervention and prevention of maternal-fetal complications.

Diagnosis

Pharmacogenomic testing involves genotyping specific loci known to influence drug metabolism, transport, or response. Commercially available platforms can detect common variants in genes such as CYP2D6, CYP2C19, CYP3A4, TPMT, and SLCO1B1. In the clinical setting, testing is typically considered for women with prior ADRs, unpredictable drug responses, or when initiating medications with established pharmacogenomic guidelines. Interpretation requires integration of genotype data with clinical context, consideration of pregnancy-specific changes, and multidisciplinary consultation with pharmacogenetics experts and maternal-fetal medicine specialists.

Treatment & Management

Management strategies informed by pharmacogenomic insights include dose adjustments, alternative drug selection, or enhanced monitoring. For example, in pregnant women identified as CYP2D6 poor metabolizers, alternative analgesics may be preferred over codeine to prevent inadequate pain relief or toxicity. Similarly, TPMT genotyping can guide thiopurine dosing in women with autoimmune conditions. Clinical pharmacists and genetic counselors play vital roles in interpreting results and optimizing individualized treatment plans. Importantly, integration of pharmacogenomic data should not delay urgent therapy but should be used to inform ongoing management and risk mitigation.

Recent Advances / Emerging Therapies

Advances in next-generation sequencing and bioinformatics have expanded the scope of pharmacogenomic profiling, enabling rapid, comprehensive assessment of multiple gene variants. Research is increasingly focused on integrating multi-omic data (genomics, proteomics, metabolomics) to refine drug response predictions. Emerging evidence supports preemptive pharmacogenomic testing in high-risk obstetric populations, such as those with epilepsy or psychiatric disorders. Additionally, ongoing studies are exploring the use of non-invasive prenatal testing (NIPT) to assess both maternal and fetal pharmacogenomic profiles, potentially informing drug selection and dosing in real time. Regulatory frameworks and clinical decision support tools are evolving to support safe implementation.

Guideline Recommendations

Authoritative bodies such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued guidelines for several gene-drug pairs relevant to pregnancy. These guidelines recommend genotyping for enzymes like CYP2D6 before prescribing codeine, and for TPMT prior to thiopurines, with specific dosing adjustments based on genotype. Obstetric organizations emphasize a multidisciplinary approach, advocating for integration of pharmacogenomic testing into preconception and antenatal care for women at elevated risk. Education of healthcare providers and patient counseling are critical components of successful guideline implementation.

Conclusion

Maternal pharmacogenomic profiling represents a transformative advance in the personalization of pharmacotherapy during pregnancy. By elucidating genetic determinants of drug response, clinicians can optimize medication selection, dosing, and monitoring, thereby enhancing maternal and fetal safety. Ongoing research, robust clinical guidelines, and interprofessional collaboration will be essential to realize the full potential of pharmacogenomics in maternal-fetal medicine. As technology advances and evidence accumulates, routine integration of pharmacogenomic testing in pregnancy is poised to become a cornerstone of precision obstetric care.